CFDE Data Portal | Search NUCLEOLIN

	Label	Description
	NUCLEOLIN Gene (Entity type)	ENSG00000115053 - nucleolin multifunctional protein
	Nucleolin Protein (Entity type)	A Protein
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 1 v 15 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE184210 0 V 1 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS

NUCLEOLIN

ENSG00000115053 - nucleolin multifunctional protein

Nucleolin

A Protein

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE108464 AZ-628 1 v 15 human up

A Gene Set from LINCS

GSE184210 0 V 1 GLUCAGON MOUSE UP

A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.